Our data suggest that p110β inhibition selectively sensitizes cells to MEK inhibition in the subset of PTEN-deficient melanomas harboring hyperactivation of RAC1 signaling, or broader dysregulation of the PREX2/RAC1/PI3Kβ axis. The gene discussed is PREX2; the disease is melanoma.